The TGA Targets Unacceptable Advertising
30 May 2017
It is illegal to advertise prescription-only products to the general public.
The TGA recently provided a reminder to health practitioners and cosmetic/beauty clinics that it is an offence for a person to publish or broadcast an advertisement that refers to Schedule 4 (prescription-only) substances. The offence carries a maximum penalty of $10,800 for an individual and $54,000 for a body corporate (from 1 July 2017 these will increase to $13,200 for individuals and $63,000 for body corporates).
The TGA reported some health practitioners and cosmetic/beauty clinics are advertising prescription-only products to the general public.
Terms that are not acceptable in advertising include:
- Botox, Dysport (botulinum toxin)
- Restylane, Perlane, Dermalive, Juvederm (hyaluronic acid)
- Collagen, Zyderm, Zyplast, Cosmoplast, Cosmoderm (collagen)
- Aquamid (polyacrylamide)
- Newfill, Nufill, Sculptra (polylactic acid).
Acceptable general terms in advertising include:
- cosmetic injections
- anti-wrinkle injections/treatments
- wrinkle and lip enhancement/fulfillment/augmentation
- injections/treatments for lips or to enhance pouting of the lips.
Other words or phrases with similar meaning may also be used, provided that they do not refer to specific products or ingredient names.
AHPRA has an increased focus on advertising by health practitioners.
If you are advertising health services, you should also ensure you are familiar with the AHPRA Guidelines for advertising regulated health services.
This blog contains general information only. We recommend you contact your medical defence organisation or insurer when you require specific advice in relation to medico-legal matters.
Doctors Let's Talk: Get Yourself A Fricking GP
Get yourself a fricking GP stat! is a conversation with Dr Lam, 2019 RACGP National General Practitioner of the Year, rural GP and GP Anesthetics trainee, that explores the importance of finding your own GP as a Junior Doctor.
25 Oct 2022
Systematic efforts to reduce harms due to prescribed opioids – webinar recording
Efforts are underway across the healthcare system to reduce harms caused by pharmaceutical opioids. This 43-min recording of a live webinar, delivered 11 March 2021, is an opportunity for prescribers to check, and potentially improve, their contribution to these endeavours. Hear from an expert panel about recent opioid reforms by the Therapeutic Goods Administration and changes to the Pharmaceutical Benefits Scheme.
14 May 2021
Diplomacy in a hierarchy: tips for approaching a difficult conversation
Have you found yourself wondering how to broach a tough topic of conversation? It can be challenging to effectively navigate a disagreement with a co-worker, especially if they're 'above' you; however, it's vital for positive team dynamics and safe patient care. In this recording of a live webinar you'll have the opportunity to learn from colleagues' experiences around difficult discussions and hear from a diverse panel moderated by Dr Kiely Kim (medico-legal adviser and general practitioner). Recorded live on 2 September 2020.
05 Oct 2020
